Biogen develops therapies for neurological diseases and disorders.
Anti-amyloid antibodies (Leqembi with Eisai, donanemab with Lilly) demonstrate plaque clearance and modest clinical benefit in symptomatic patients; real opportunity lies in earlier intervention before irreversible neurodegeneration.